DataMeds unit Corexa lines up peptide suppliers ahead of FDA compounding policy
The company says its distribution arm, licensed in all 50 states, will work with its network of more than 6,500 independent pharmacies.
TR
By Tom Reyes · Markets Editor
Oct 16 06:00 ETSource: Stock Titan
The wire
- 01DataMeds AI said subsidiary Corexa Health has begun reviewing drug-substance suppliers and plans to formalize contracts in coming weeks, responding to the FDA's proposed interim policy on compounding certain peptides.
- 02The proposal follows an advisory committee recommendation to loosen restrictions on six peptides and signals how fast distributors and pharmacies intend to move once rules change.
- 03The policy is not yet effective; DataMeds expects the market to be predominantly cash pay initially, and the plans are company statements, not completed contracts. MEDS closed 7.72% lower on Oct 16.
From the source
Read at stocktitan.netFDA proposes a policy for pharmacies to prepare certain peptides. DataMeds cites 6,500+ pharmacies.
Corexa Pharmacy has begun reviewing peptide suppliers and intends to formalize contracts in the coming weeks.
